FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to immunology and biotechnology. Claimed is isolated monoclonal antibody, inducing cytotoxicity with respect to cancer cells, produced by hybridome, deposited in collection ID AC under number 051206-01, or its antigen-binding fragment. Described are: chimeric and hymanised versions, obtained from said antibody. Described is hybridome, producing monoclonal antibody and deposited in collection ID AC under number 051206-01, as well as composition based on said antibody for treatment of human cancer tumour.
EFFECT: application of invention ensures versions of monoclonal antibodies capable of inducing cytotoxicity in vitro in the absence of effector cells with respect to lung adenocarcenoma cells, which can be applied in tumour therapy.
5 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-SPECIFIC ANTIBODIES INTENDED FOR USE IN TREATMENT OF URINARY TRACT NEOPLASM | 2017 |
|
RU2766358C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING EFFECTIVENESS OF ANTIBODY FOR MEDICAL APPLICATION WITH USING COMPOUNDS POTENTIATING NK-CELLS | 2004 |
|
RU2396981C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| ANTIBODY BOUND WITH CARBONIC ANHYDRASE, AND USE THEREOF | 2017 |
|
RU2727682C1 |
| CANCER TREATMENT USING TARGETED ANTIBODIES IN VIVO | 2011 |
|
RU2642305C2 |
| MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
| MONOCLONAL ANTIBODIES TO CD44, INTENDED FOR USE IN TREATING SQUAMOUS CELL CARCINOMA OF THE HEAD AND THE NECK | 2011 |
|
RU2599447C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2774414C2 |
| COMPOSITIONS CONTAINING ANTI-SEAMS 1 AND ANTI-PD ANTIBODIES FOR CANCER THERAPY | 2014 |
|
RU2697522C1 |
| COMBINATION CONTAINING MULTIFUNCTIONAL ANTIBODIES REDIRECTING T-CELLS AND CONTROL POINT MODULATORS, AND ITS APPLICATIONS | 2017 |
|
RU2773655C2 |
